

# Staying on Target with Continuous Dialysis

Sevag Demirjian\* and William H. Fissell†

*Clin J Am Soc Nephrol* 10: 7–8, 2015. doi: 10.2215/CJN.11251114

“It was through the evolution of this filtration-reabsorption system that the kidney came to be almost entirely responsible for the composition of the internal environment of the body, manufacturing it, as we have said, in reverse, by saving some things from the glomerular filtrate and rejecting others. Among the substances known to be reabsorbed by the tubules in man, for example, are water, sodium, potassium, calcium, chloride, bicarbonate, phosphate, sulfate, glucose, fructose, a large variety of amino acids, and several vitamins and hormones. There are certainly many others on which no quantitative observations are available.” (1)

As the proverbial primitive man and woman ventured on to dry land, their kidneys continued to excrete wastes, but now with extreme frugality of water and salt. Kidneys had to accomplish high-volume filtration, as in their previous marine habitat, so they could excrete novel toxins and filter and secrete metabolic wastes, but now they had to also perpetually reabsorb salt and water in the tubule. Some additional solutes are reabsorbed so completely that their clearance approaches zero, whereas others are actively secreted so that their clearance approaches renal plasma flow. Inasmuch as filtration has become synonymous with renal function in the context of RRT, it is easy to overlook the robust and dynamic contribution of the renal tubule to homeostasis.

Almost four decades have passed since Kramer *et al.* (2) and Paganini *et al.* (3) introduced and popularized an ingeniously simple modality of dialysis. Continuous dialysis capitalized on advances of membrane technology and promised more physiologic and continuous renal support in the bed-bound critically ill patient. The opportunity to provide continuous small solute clearance raised the question of dose targeting: when compared with a healthy glomerular filtration rate of 120–140 ml/min, what is the best dose of continuous renal replacement to prescribe? Two large well-conducted studies failed to demonstrate improved survival with increased dialysis dose in the critically ill patient (4,5). We have conclusively exhausted that line of inquiry. As we increased dialysis duration in pursuit of the very high standard set by glomerular filtration, we perhaps once more underestimated the contribution of the renal tubule to homeostasis. Our bedside gadgets are incomplete mimics of the organs refined by millions of years of ceaseless tinkering by Mother Nature, and continuous RRT (CRRT) removes small solutes, including amino acids, vitamins, trace

elements, hormones, minerals, antibiotics and vaso-pressors, and wastes and water. As the CRRT dose increases, so do the off-target effects of therapy (6–9).

It is established that phosphate removal during intermittent dialysis does not follow the same linear two-compartment kinetics of urea (10,11). Phosphate is effectively removed with increased frequency or duration of dialysis treatments (12). In this issue of the journal, Sharma *et al.* report measureable reductions in red blood cell concentration of 2,3 diphosphoglycerate contemporaneous with CRRT-induced phosphate depletion (13). Although the study based its conclusions on a relatively small sample size, it highlights the significant cumulative phosphate drain with time and its putative downstream mediator effect on tissue oxygen delivery in the critically ill patient (14). Moreover, CRRT-induced alkalemia, another dose-dependent side effect that follows a similar temporal pattern, will also shift the oxygen-hemoglobin curve further to the left because of the Bohr effect (reduces oxygen release in peripheral tissues) (15). This is especially disconcerting in this patient population where compromised oxygenation in the setting of renal failure, further compounded by volume burden, is the main determinant of mortality (16).

Continuous renal support saves lives by correcting electrolyte and acid-base derangements and controlling extracellular fluid volume in the critically ill. Nephrologists aspire to improve the disappointing survival rates in severe AKI, and the results of the VA/NIH Acute Renal Failure Trial Network Study and the Randomized Evaluation of Normal versus Augmented Level Replacement Therapy Study trials have redirected us from a focus on urea clearance to considering middle molecules and protein-bound solutes. Clearance of middle molecules and protein-bound uremic solutes will require increases in blood and dialysate flow rates (17–22). In an ideal scenario, we would know the identities of the molecular mediators of uremia and adjust dialysis settings to optimize their clearance. It is becoming more apparent that the off-target effects of CRRT, particularly depletion of needed metabolites and removal of essential drugs, are an underexplored opportunity to improve outcomes in severe AKI. Sharma and colleagues have added an important and novel mechanism by which unanticipated off-target effects of CRRT could undermine our efforts to support the critically ill patient.

## Disclosures

None.

\*Department of Nephrology and Hypertension, Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, Ohio; and †Department of Nephrology and Hypertension, Vanderbilt University, Nashville, Tennessee

## Correspondence:

Dr. William H. Fissell, Department of Nephrology and Hypertension, Vanderbilt University Medical Center, 1161 21st Avenue South, S-3223 MCN, Nashville, TN 37232-2372. Email: william.fissell@vanderbilt.edu

## References

- Smith HJ *From Fish to Philosopher: The Story of Our Internal Environment*, Boston, Little Brown & Co., 1959
- Kramer P, Wigger W, Rieger J, Matthaer D, Scheler F: [Arteriovenous haemofiltration: a new and simple method for treatment of over-hydrated patients resistant to diuretics]. *Klin Wochenschr* 55: 1121–1122, 1977
- Paganini EP, Nakamoto S: Continuous slow ultrafiltration in oliguric acute renal failure. *Trans Am Soc Artif Intern Organs* 26: 201–204, 1980
- Bellomo R, McGrath B, Boyce N: Effect of continuous venovenous hemofiltration with dialysis on hormone and catecholamine clearance in critically ill patients with acute renal failure. *Crit Care Med* 22: 833–837, 1994
- Palevsky PM, Zhang JH, O'Connor TZ: Intensity of renal support in critically ill patients with acute kidney injury. *N Engl J Med* 359: 7–20, 2008
- Connor MJ Jr, Salem C, Bauer SR, Hofmann CL, Groszek J, Butler R, Rehm SJ, Fissell WH: Therapeutic drug monitoring of piperacillin-tazobactam using spent dialysate effluent in patients receiving continuous venovenous hemodialysis. *Antimicrob Agents Chemother* 55: 557–560, 2011
- Bauer SR, Salem C, Connor MJ Jr, Groszek J, Taylor ME, Wei P, Tolwani AJ, Fissell WH: Pharmacokinetics and pharmacodynamics of piperacillin-tazobactam in 42 patients treated with concomitant CRRT. *Clin J Am Soc Nephrol* 7: 452–457, 2012
- Afshartous D, Bauer SR, Connor MJ, Aduroja OA, Amde M, Salem C, Groszek JJ, Fissell WH: Pharmacokinetics and pharmacodynamics of imipenem and meropenem in critically ill patients treated with continuous venovenous hemodialysis. *Am J Kidney Dis* 63: 170–171, 2014
- Nolin TD, Aronoff GR, Fissell WH, Jain L, Madabushi R, Reynolds K, Zhang L, Huang SM, Mehrotra R, Flessner MF, Leyboldt JK, Witcher JW, Zineh I, Archdeacon P, Roy-Chaudhury P, Goldstein SL: Pharmacokinetic assessment in patients receiving continuous RRT: Perspectives from the Kidney Health Initiative [published online ahead of print September 4, 2014]. *Clin J Am Soc Nephrol*
- Haas T, Hillion D, Dongradi G: Phosphate kinetics in dialysis patients. *Nephrol Dial Transplant* 6[Suppl 2]: 108–113, 1991
- Spalding EM, Chamney PW, Farrington K: Phosphate kinetics during hemodialysis: Evidence for biphasic regulation. *Kidney Int* 61: 655–667, 2002
- Mucsi I, Hercz G, Uldall R, Ouwendyk M, Francoeur R, Pierratos A: Control of serum phosphate without any phosphate binders in patients treated with nocturnal hemodialysis. *Kidney Int* 53: 1399–1404, 1998
- Sharma S, Brugnara C, Betensky RA, Waikar SS: Reductions in red blood cell 2,3 diphosphoglycerate concentration during continuous renal replacement therapy. *Clin J Am Soc Nephrol* 10: 74–79, 2015
- Demirjian S, Teo BW, Guzman JA, Heyka RJ, Paganini EP, Fissell WH, Schold JD, Schreiber MJ: Hypophosphatemia during continuous hemodialysis is associated with prolonged respiratory failure in patients with acute kidney injury. *Nephrol Dial Transplant* 26: 3508–3514, 2011
- Demirjian S, Teo BW, Paganini EP: Alkalemia during continuous renal replacement therapy and mortality in critically ill patients. *Crit Care Med* 36: 1513–1517, 2008
- Demirjian S, Chertow GM, Zhang JH, O'Connor TZ, Vitale J, Paganini EP, Palevsky PM; VA/NIH Acute Renal Failure Trial Network: Model to predict mortality in critically ill adults with acute kidney injury. *Clin J Am Soc Nephrol* 6: 2114–2120, 2011
- Scribner BH, Babb AL: Evidence for toxins of “middle” molecular weight. *Kidney Int Suppl* (3): 349–351, 1975
- Vanholder RC, De Smet RV, Ringoir SM: Assessment of urea and other uremic markers for quantification of dialysis efficacy. *Clin Chem* 38: 1429–1436, 1992
- Lesaffer G, De Smet R, Lameire N, Dhondt A, Duym P, Vanholder R: Intradialytic removal of protein-bound uraemic toxins: role of solute characteristics and of dialyser membrane. *Nephrol Dial Transplant* 15: 50–57, 2000
- Meyer TW, Walther JL, Pagtalunan ME, Martinez AW, Torkamani A, Fong PD, Recht NS, Robertson CR, Hostetter TH: The clearance of protein-bound solutes by hemofiltration and hemodiafiltration. *Kidney Int* 68: 867–877, 2005
- Jourde-Chiche N, Dou L, Cerini C, Dignat-George F, Vanholder R, Brunet P: Protein-bound toxins—update 2009. *Semin Dial* 22: 334–339, 2009
- Hofmann CL, Fissell WH: Middle-molecule clearance at 20 and 35 ml/kg/h in continuous venovenous hemodiafiltration. *Blood Purif* 29: 259–263, 2010

Published online ahead of print. Publication date available at [www.cjasn.org](http://www.cjasn.org).

See related article, “Reductions in Red Blood Cell 2,3-Diphosphoglycerate Concentration during Continuous Renal Replacement Therapy,” on pages 74–79.